Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Gossamer Bio, Inc.NASDAQ: GOSS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $6.3M rose 162.1% year over year, ahead of the -16.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 117.5% from the prior quarter. Over 3 fiscal years it compounded at -37.2% a year.
Context
- Stock-based compensation amounted to 21.8% of revenue in FY2025, up 3.8 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +162.1% holds above the trailing-twelve-month pace of -16.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.56M USD
- Year-over-year change
- -48.8%
- 4-year CAGR
- -24.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.56M | -48.8% |
| FY2024 | 2024-12-31 | 20.62M | -27.7% |
| FY2023 | 2023-12-31 | 28.52M | -33.0% |
| FY2022 | 2022-12-31 | 42.55M | +32.9% |
| FY2021 | 2021-12-31 | 32.01M | — |
Stock-Based Compensation vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 stock-based compensation of $14.45M is the 4th largest of the 9 companies compared; the peer median is $13.03M.
- Its year-over-year change of -16.0% is the 5th highest of 8, against a peer median of -7.4%.
- Stock-based compensation amounts to 26.0% of revenue for GOSS, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.64M | -7.4% | -5.4% | 39.4% | |
| LTM Mar 2026 | $33.61M | -24.5% | +6.3% | 58.0% | |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $14.45M | -16.0% | -37.2% | 26.0% | |
| LTM Mar 2026 | $13.21M | -40.1% | — | — | |
| LTM Mar 2026 | $12.84M | +21.4% | +0.9% | 4.3% | |
| LTM Mar 2026 | $12.55M | +2.5% | +2.8% | 18.0% | |
| LTM Mar 2026 | $6.73M | +88.8% | +25.6% | — | |
| LTM Dec 2025 | $5.38M | — | — | 4.6% | |
| Peer median (excluding GOSS) | $13.03M | -7.4% | +4.6% | 20.1% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 32.01M | 42.55M | 28.52M | 20.62M | 10.56M |
| Change in Working Capital | 774K | (4.46M) | (14.84M) | 39.46M | (13.63M) |
| Accounts Receivables | 0 | 0 | 0 | (5.34M) | (6.89M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.43M) | (1.81M) | 3.99M | (1.66M) | (2.75M) |
| Other Working Capital | 5.2M | (2.65M) | (18.83M) | 46.45M | (3.99M) |
| Other Non-Cash Items | 7.17M | (177K) | 2.6M | (11.17M) | 1.18M |
| Operating Cash Flow | (188.89M) | (187.03M) | (159.16M) | (3.47M) | (171.27M) |
| Capital Expenditures | (1.62M) | (475K) | 0 | 0 | (79K) |
| Acquisitions (Net) | 0 | (65K) | 0 | 0 | 0 |
| Purchases of Investments | (152.03M) | (238.06M) | (441.67M) | (494.78M) | (227.11M) |
| Sales of Investments | 36.23M | 237.5M | 330.7M | 523.8M | 383.54M |
| Other Investing Activities | (75K) | 65K | 0 | 0 | 0 |
| Investing Cash Flow | (117.43M) | (1.04M) | (110.97M) | 29.02M | 156.36M |
| Debt Repayment | 0 | (5.81M) | (11.61M) | (12.58M) | 0 |
| Common Stock Issued | 0 | 119.95M | 201.32M | 464K | 6.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 629K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.33M | 2.95M | 444K | 0 | 0 |
| Financing Cash Flow | 3.33M | 117.09M | 190.15M | (11.49M) | 6.43M |
| Effect of Forex Changes | (165K) | (517K) | 110K | (102K) | 141K |
| Net Change in Cash | (303.15M) | (71.49M) | (79.86M) | 13.97M | (8.34M) |
| Free Cash Flow | (190.51M) | (187.51M) | (159.16M) | (3.47M) | (171.35M) |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.